We have published a report on our recent research and development conference - Health Research - Partnership for Success which was jointly hosted with the BioIndustry Association (BIA) and the NIHR Office for Clinical Research Infrastructure (NOCRI).
Join influential leaders across all the health sectors for our 2013 Annual Conference, entitled '360° of health', on Thursday 25 April at Westminster Bridge Park Plaza, London.
Isambard Kingdom Brunel and the railways, Sir Alexander Fleming and penicillin, Sir Frank Whittle and the jet engine, Francis Crick and James Watson and DNA. The UK has a rich heritage when it comes to the research and development of new technologies and life-changing discoveries and the...
This year’s R&D Conference will explore how major scientific advances in biomedicine are transforming both the development and delivery of new medicines and could fundamentally change the way the healthcare system is organised.
As the ABPI launches an update to its white paper of April 2009 ‘The stratification of disease for personalised medicines’ Dr Louise Leong looks at what has been achieved and what still needs to be done to support a stratified medicine approach in the UK.
Following the success of last year’s roadshows, the ABPI NHS Partnership team is running a new series of regional events in 2014.
Today we have published a write-up of an event we held in late April on ‘Understanding the Early Access to Medicines Scheme’ (EAMS).
The pharmaceutical industry in the UK is at a crucial juncture. On the one hand, the industry has driven cutting-edge scientific research and development for decades, producing innovative medicines responsible for reducing mortality and morbidity.
One problem with the oft-heard mantra of "putting patients at the centre of what we do" is that every patient is different. We have dustmen and professors, housewives and high-flyers, we have rare cancers and common ones, we have the cured and the dying. So how do you get patients involved in...
As an industry that, at its root, exists to improve health and meet patient needs, we have a responsibility to engage with patients and society to develop the best possible treatment pathways for them. This is a hot topic in medicines development, from increasing patient involvement in research...
This extended analysis was authored by Colette Goldrick, ABPI Director of NHS Engagement, in response to today's (5 April) House of Lords Long-Term Sustainability of the NHS Committee report.